CD37 is significantly downregulated in aggressive B-cell lymphoma cell lines resistant to rituximab; nevertheless, this reduction in CD37 expression does not diminish the therapeutic efficacy of CD37-targeted CAR T-cell therapy [49]. The gene discussed is CD37; the disease is B-cell non-Hodgkin lymphoma.